CAJ | 학술논문

目的通过不同部位胆管癌栓的疗效对比,进一步探讨胆道癌栓的预后及其影响因素.方法随访第二军医大学东方肝胆外科医院2000年1月至2003年12月手术治疗的原发性肝癌伴胆管癌栓病人共50例,按胆管癌栓的部位分为A、B、C、D组共4组.结果 A、B、C、D各组的中位生存时间分别为11.6个月、2.1个月,8.0个月和7.6个月.B组较其他各组具有显著统计学意义(P<0.05).结论原发性肝癌伴胆管癌栓手术治疗可取得较好的疗效,但是不同部位的胆道癌栓的预后并不一样,以伴胆管左支癌栓的预后为最差.
목적 통과불동부위담관암전적료효대비,진일보탐토담도암전적예후급기영향인소.방법 수방제이군의대학동방간담외과의원2000년1월지2003년12월수술치료적원발성간암반담관암전병인공50례,안담관암전적부위분위A、B、C、D조공4조.결과 A、B、C、D각조적중위생존시간분별위11.6개월、2.1개월,8.0개월화7.6개월.B조교기타각조구유현저통계학의의(P<0.05).결론 원발성간암반담관암전수술치료가취득교호적료효,단시불동부위적담도암전적예후병불일양,이반담관좌지암전적예후위최차.
Objective To observe the prognosis of hepatocellular carcinoma (HCC) patients with cancer embolus of biliary tract (CEBT).Methods The clinical data of 50 HCC patients with CEBT underwent hepatectomy and thrombeetomy in our hospital from January 2000 to December 2003 were retrospectively analyzed.All the patients were divided into four groups (A, B, C and D) based on distribution and location of CEBT.Results The 0.5-, 1-, 2-and 3-year survival rates were 51.2%, 31.7%, 19.5% and 12.2%, respectively.The median survival time was 11.6, 2.1, 8.0 and 7.6 months in group A, B, C and D, respectively.Significant difference was found in the survival time between group B with CEBT located in the left hepatic duct and other groups (P < 0.05).Conclosion Surgery remainsthe most effective treatment for HCC with CEBT.But the therapeutical effect is not the same for CEBT of different locations.The prognosis is the worst in those patients with CEBT lo-cated in the left hepatic duct.